Corifact market outlook improves on rising global demand

The Business Research Company says the global Corifact market is poised for faster growth through 2035, driven by more bleeding disorders, more surgeries and broader use of fibrinogen concentrates. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Corifact is used to help control bleeding in patients with low fibrinogen levels, including people facing trauma, surgery and liver disease. - The market matters because demand for fast-acting hemostatic treatments is rising alongside more emergency surgeries, an aging population and better coagulation diagnostics. - The report also points to growing use of plasma-derived therapies and fibrinogen concentrates in hospital care.

What happened: - The Business Research Company released a Corifact market report covering 2026-2035. - The company says the market is gaining attention because of its role in bleeding disorders and surgical bleeding management. - The report says the market expanded in recent years on better recognition of fibrinogen deficiency, trauma care improvements, stronger surgical bleeding protocols, approvals for plasma-derived therapies and wider hospital adoption. - The report says North America held the largest global market share in 2025. - The report says Asia-Pacific will be the fastest-growing region over the forecast period.

The details: - Corifact is a fibrinogen concentrate that helps the body form blood clots and prevent excessive bleeding. - The treatment is used primarily in patients with fibrinogen deficiency or low fibrinogen levels. - The report says future growth will be driven by more emergency surgeries, an aging population, more trauma centers, better diagnostic methods and stronger demand for quick hemostatic agents. - The report highlights trends including greater use of fibrinogen concentrates, rapid bleeding control, more trauma and surgical care, expanded hospital-based hemostasis management and wider adoption in liver disease. - Rising bleeding disorders are a key growth catalyst because they reduce the blood’s ability to clot properly. - The report says the rise in bleeding disorders is linked to better diagnosis, more awareness, advances in genetic testing, changing lifestyles and underlying health conditions. - The report cites a December 2023 UK Haemophilia Centre Doctors’ Organisation report that documented thousands of patients living with haemophilia A and B and related clotting factor deficiencies. - Corifact addresses bleeding issues caused by factor XIII deficiency by replacing the missing clotting factor and supporting stable clot formation. - The report also flags rising demand for biological products as a driver for market growth. - Biological products are complex medicines derived from living organisms and used to diagnose, prevent and treat disease. - The report says environmental concerns, consumer awareness and demand for alternatives to synthetic drugs are helping lift interest in biological products. - The report says Corifact supports the biological product sector through formulation and delivery methods that improve stability, bioavailability and efficacy. - A 2025 US Assistant Secretary for Planning and Evaluation report is cited as showing biosimilar revenues vary widely and regulatory changes could lower development costs and boost lifetime revenues. - The report says the growing number of surgical procedures is also expanding demand. - Minimally invasive procedures grew 7% in 2023, according to the American Society of Plastic Surgeons in June 2024.

Between the lines: - The report frames Corifact as part of a broader shift toward faster, more targeted bleeding control in hospitals. - Asia-Pacific’s projected growth suggests demand may be shifting toward markets with expanding surgical capacity and trauma care infrastructure. - The report’s emphasis on diagnostics and emergency care suggests adoption may rise as hospitals identify fibrinogen deficiency earlier and treat bleeding faster.

What's next: - The market analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and future trend analysis. - The company also provides a free sample report and the full report online: More information and the full report.

The bottom line: - Corifact’s market outlook is improving as bleeding disorders, surgical demand and plasma-derived therapies converge into a larger global treatment need.